ADVERTISEMENT
Podcasts
Joseph Jacob, MD, Reviews SunRISe-1 Trial Progress in High-Risk, Non–Muscle-Invasive Bladder Cancer
03/02/2022
Joseph Jacob, MD, Upstate University Hospital, highlights the progress of SunRISe-1: a phase 2b study of TAR-200 plus cetrelimab, TAR-200 alone, or cetrelimab alone in participants with high-risk nonmuscle-invasive bladder cancer unresponsive to Bacillus Calmette-Guérin who are ineligible for or decline radical cystectomy.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Visit the OLN Excellence Forums
Advertisement
Advertisement
Advertisement